-

Rallybio to Present at the 29th Annual Credit Suisse Virtual Healthcare Conference

NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio, a biopharmaceutical company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders, today announced that Steve Uden, M.D., Co-Founder and Chief Operating Officer, will present at the 29th Annual Credit Suisse Virtual Healthcare Conference on Tuesday, November 10, 2020 at 5:00 p.m. Eastern Time.

A live webcast of the presentation is accessible here, and a replay of the webcast will be available in the “Investor” section of Rallybio’s website for 90 days following the conference.

About Rallybio

Rallybio is a biopharmaceutical company focused on identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. Since its launch in January 2018, Rallybio has built a portfolio of promising product candidates, which are now in development to address rare diseases in the areas of hematology, immuno-inflammation, and metabolism. The Company’s mission is being advanced by a team of highly experienced biopharma industry leaders with extensive research, development, and rare disease expertise. Rallybio is headquartered in New Haven, Connecticut, with an additional facility at the University of Connecticut’s Technology Incubation Program in Farmington, Connecticut. For more information, please visit www.rallybio.com.

Contacts

Investors
Laura Ekas, PhD
917-439-0374
lekas@rallybio.com

Media
Tara DiMilia
908-369-7168
tara.dimilia@tmstrat.com

Rallybio


Release Versions
Hashtags

Contacts

Investors
Laura Ekas, PhD
917-439-0374
lekas@rallybio.com

Media
Tara DiMilia
908-369-7168
tara.dimilia@tmstrat.com

Social Media Profiles
More News From Rallybio

Rallybio Reports Fourth Quarter and Full Year 2021 Financial Results

NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided an update on recent corporate developments. “Following our successful initial public offering in August 2021, we continue to advance our broad portf...

Rallybio to Present at the Cowen 42nd Annual Health Care Conference

NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that Martin Mackay, Ph.D., Chief Executive Officer of Rallybio, will participate in a panel discussion, “Neuromuscular” at the Cowen 42nd Annual Health Care Conference on Monday, March 7, 2022 at 9:10 a.m. ET. A webcast of the panel discus...

Ami Bavishi Joins Rallybio to Lead Investor Relations and Corporate Communications

NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that Ami Bavishi has joined as the company’s Head of Investor Relations and Corporate Communications. Ms. Bavishi brings more than 10 years of experience to Rallybio and will be responsible for overseeing Rallybio’s investor relations (IR)...
Back to Newsroom